Since the anti-malarial drugs chloroquine and hydroxychloroquine entered the big stage of "new coronary pneumonia, old medicine and new use", the storm has been constant. Sweden, France and many other countries discontinued (hydroxy) chloroquine treatment of COVID-19 patients. The former leader of the FDA condemned the emergency use authorization (EUA) of anti-malarial drugs, which he believes undermines the scientific authority of the FDA. The official website of the US Centers for Disease Control and Prevention (CDC) has published a medication guide titled "Clinicians' Information on Treatment Options for Patients with New Coronary Pneumonia", which includes the key doses of the drugs chloroquine and hydroxychloroquine for COVID-19 Information, but only published 3 days, CDC deleted this guide from the official website. And Rick Bright, director of the US Agency for Advanced Research and Development in Biomedicine (BARDA), was forced to leave because he resisted funding for the promotion of unproven antimalarial drugs for COVID-19.
In terms of clinical research, earlier this month, researchers in Brazil stopped some studies of hydroxychloroquine because some patients experienced heart rhythm problems after undergoing tests with two higher doses of drugs; conducted by the US Veterans Health Administration Medical Center After the study, it was found that the experimental group of "receiving hydroxychloroquine treatment" new coronary pneumonia "has a higher mortality rate"! The researchers also tested the effect of combining with azithromycin, the result is that whether it is combined with azithromycin, will not reduce the risk of using a ventilator.
Recently, chloroquine and hydroxychloroquine have recurred. According to an internal e-mail published by the American magazine Vanity Fair, the Trump administration pressured federal government health officials to provide the public with the malaria drug chloroquine for COVID treatment without medical supervision -19. This strategy also caused panic and opposition from scientists and doctors of some federal health agencies, who expressed their refusal to suspend drug regulation.
This Friday, the FDA released a new drug safety report. This report is a drug safety bulletin on known side effects of hydroxychloroquine and chloroquine, including serious and potentially life-threatening heart rhythm problems. This is the first time the FDA has issued relevant content for the treatment of COVID-19 patients with hydroxychloroquine and chloroquine since the emergency authorization of hydroxychloroquine and chloroquine.
According to the FDA, according to the case report in the database of the FDA's adverse event reporting system, it is known that COVID-19 patients have serious heart rhythm problems when receiving drugs or similar compounds chloroquine (usually combined with the antibiotic azithromycin). The drugs used to treat arthritis, lupus and malaria ten years ago already knew their side effects on the heart. Although the FDA has granted hydroxychloroquine and chloroquine emergency authorization for the treatment of COVID-19 as early as a month ago, it was only earlier this week that hydroxychloroquine was approved by the FDA to enter the phase III clinical trial for the treatment of COVID-19. In the report, the FDA mentioned that the FDA has not approved hydroxychloroquine and chloroquine for the treatment or prevention of COVID-19.
In the report, the FDA warned the public not to use hydroxychloroquine and chloroquine for treatment without authorization. The results of clinical trials have not yet been announced, and emergency authorizations for hydroxychloroquine and chloroquine only apply to inpatients. The FDA also encourages healthcare professionals to carefully screen and monitor each patient to help mitigate these risks.
Currently, clinical trials on hydroxychloroquine are underway. According to the Wall Street Journal, the researchers plan to recruit 200,000 patients to participate in more than 100 studies on hydroxychloroquine.
A few days ago, the clinical research data of the new crown "miracle drug" Remdesivir (Remdesivir) flowed out, and the results were not satisfactory. During the COVID-19 pandemic, people from all walks of life in various countries hope to find effective drugs as soon as possible, but for drugs, trials are still needed to prove their safety and effectiveness, and political public opinion cannot be a lever for controlling science.